600196 复星医药
交易中 04-02 10:33:13
资讯
新帖
简况
4月1日复星医药现327.6万元大宗交易
证券之星 · 04-01 17:21
4月1日复星医药现327.6万元大宗交易
复星医药(600196.SH)控股子公司药品HLX319获临床试验批准
智通财经网 · 04-01 16:56
复星医药(600196.SH)控股子公司药品HLX319获临床试验批准
复星医药：重组人透明质酸酶注射液获批临床 累计投入2673万元
财中社 · 03-31 17:52
复星医药：重组人透明质酸酶注射液获批临床 累计投入2673万元
复星医药子公司FXB0871获批临床试验 用于局部晚期或转移性实体瘤
财中社 · 03-31 17:52
复星医药子公司FXB0871获批临床试验 用于局部晚期或转移性实体瘤
每周股票复盘：复星医药（600196）2025年归母净利润增21.69%
证券之星 · 03-29
每周股票复盘：复星医药（600196）2025年归母净利润增21.69%
复星医药（600196）2025年年报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 03-26
复星医药（600196）2025年年报简析：营收净利润同比双双增长，盈利能力上升
复星医药(02196)拟派发末期股息每股0.39元
智通财经 · 03-25
复星医药(02196)拟派发末期股息每股0.39元
复星医药(02196)控股子公司拟新增开展融资租赁业务
智通财经 · 03-24
复星医药(02196)控股子公司拟新增开展融资租赁业务
复星医药：关于2026年续聘会计师事务所的公告
证券日报 · 03-24
复星医药：关于2026年续聘会计师事务所的公告
复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展
智通财经 · 03-24
复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展
复星医药最新公告：2025年净利润33.71亿元同比增长21.69%
证券之星 · 03-24
复星医药最新公告：2025年净利润33.71亿元同比增长21.69%
复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月20日股价下跌1.58%
证券之星 · 03-20
复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月20日股价下跌1.58%
复星医药子公司硫代硫酸钠注射液药品注册申请获国家药监局批准
美股速递 · 03-20
复星医药子公司硫代硫酸钠注射液药品注册申请获国家药监局批准
复星医药(600196.SH)： HLX18用于多种实体瘤治疗开展Ⅰ期临床试验获批准
智通财经 · 03-20
复星医药(600196.SH)： HLX18用于多种实体瘤治疗开展Ⅰ期临床试验获批准
复星医药(600196.SH)：硫代硫酸钠注射液药品注册申请获批准
智通财经网 · 03-20
复星医药(600196.SH)：硫代硫酸钠注射液药品注册申请获批准
复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月16日股价上涨0.23%
证券之星 · 03-16
复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月16日股价上涨0.23%
复星医药(600196.SH)：HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌(sqNSCLC)治疗获批开展临床试验
智通财经 · 03-16
复星医药(600196.SH)：HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌(sqNSCLC)治疗获批开展临床试验
复星医药最新公告：控股子公司用于治疗雄激素脱发的药品LBP-ShC4获临床试验批准
证券之星 · 03-16
复星医药最新公告：控股子公司用于治疗雄激素脱发的药品LBP-ShC4获临床试验批准
每周股票复盘：复星医药（600196）三款新药获临床试验批准
证券之星 · 03-15
每周股票复盘：复星医药（600196）三款新药获临床试验批准
复星医药(600196.SH)控股子公司FXS0683片获临床试验批准
智通财经网 · 03-13
复星医药(600196.SH)控股子公司FXS0683片获临床试验批准
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.26,"timestamp":1775097193000,"preClose":27.07,"halted":0,"volume":14085951,"delay":0,"changeRate":0.007,"floatShares":2118000000,"shares":2670000000,"eps":1.4872,"marketStatus":"交易中","change":0.19,"latestTime":"04-02 10:33:13","open":27.02,"high":27.29,"low":26.83,"amount":382000000,"amplitude":0.017,"askPrice":27.27,"askSize":142,"bidPrice":27.26,"bidSize":49,"shortable":0,"etf":0,"ttmEps":1.4872,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1775100600000},"marketStatusCode":2,"adr":0,"adjPreClose":27.07,"symbolType":"stock","openAndCloseTimeList":[[1775093400000,1775100600000],[1775106000000,1775113200000]],"highLimit":29.78,"lowLimit":24.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":18.329747,"roe":"7.03%","epsLYR":1.27,"committee":-0.791003,"marketValue":72796000000,"turnoverRate":0.0066,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.74,"timestamp":1775097158567,"preClose":20.46,"halted":0,"volume":1226000,"delay":0,"premium":"-33.16"},"floatMarketCap":57750000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2624599418","title":"4月1日复星医药现327.6万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599418?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035285,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日复星医药发生大宗交易，交易数据如下：大宗交易成交价格25.2元，相对当日收盘价折价6.91%，成交13万股，成交金额327.6万元，买方营业部为民生证券股份有限公司北京第一分公司，卖方营业部为中泰证券股份有限公司杭州湖墅南路证券营业部。近三个月该股共发生3笔大宗交易，合计成交9871.0手，折价成交1笔。截至2026年4月1日收盘，复星医药报收于27.07元，上涨1.65%，换手率1.36%，成交量28.84万手，成交额7.77亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600196","BK0060","BK0012","BK0175","BK0183","BK0096","BK0187","BK1515","BK1593","BK0028","BK0196","BK1191","02196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669596","title":"复星医药(600196.SH)控股子公司药品HLX319获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669596","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624669596?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:56","pubTimestamp":1775033772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX319用于HER2阳性早期或局晚期乳腺癌新辅助治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年2月，集团现阶段针对HLX319的累计研发投入约为人民币3,387万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02196","BK1593","BK0060","BK0096","BK0183","BK0175","600196","BK0188","BK1191","BK0187","BK1515","BK0239","BK0012","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623830096","title":"复星医药：重组人透明质酸酶注射液获批临床 累计投入2673万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623830096","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623830096?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:52","pubTimestamp":1774950720,"startTime":"0","endTime":"0","summary":"3月31日，复星医药（600196/02196）发布公告，控股子公司复宏汉霖收到国家药品监督管理局同意开展HLXTE-HAase02（重组人透明质酸酶注射液）Ⅰ期临床试验的批准。该药品旨在促进皮下注射或皮下输注药物的扩散和吸收，计划于条件具备后在中国境内开展相关临床研究。截至2026年2月，集团针对HLXTE-HAase02的累计研发投入约为2673万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690543616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0028","BK0183","BK0196","BK1191","BK0060","600196","BK0239","BK0187","BK0096","BK0175","02196","BK0012","BK0188","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623530018","title":"复星医药子公司FXB0871获批临床试验 用于局部晚期或转移性实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2623530018","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623530018?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:52","pubTimestamp":1774950720,"startTime":"0","endTime":"0","summary":"3月31日，复星医药（600196/02196）发布公告，控股子公司药品获得临床试验批准。公司控股子公司复星医药产业近日收到国家药品监督管理局的批准，允许其开展FXB0871用于局部晚期或转移性实体瘤的I期临床研究。该药物是公司与Teva合作开发的PD-1靶向型IL-2融合蛋白，具有增强T细胞活性及降低全身毒性的特点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690544196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK0183","BK1515","BK0187","BK0175","600196","BK1593","BK0096","BK0239","BK0012","BK0060","BK0196","BK0028","BK1191","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623870923","title":"每周股票复盘：复星医药（600196）2025年归母净利润增21.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623870923","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623870923?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:44","pubTimestamp":1774719849,"startTime":"0","endTime":"0","summary":"本周关注点来自业绩披露要点：复星医药2025年归母净利润33.71亿元，同比上升21.69%。公司公告汇总复星医药2025年实现营业收入416.62亿元，同比增长1.45%；归属于上市公司股东的净利润33.71亿元，同比增长21.69%；扣除非经常性损益的净利润23.40亿元，同比增长1.12%。上海复星医药（集团）股份有限公司对上海复星高科技集团财务有限公司截至2025年12月31日的经营资质、业务和风险状况进行了评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000486","title":"复星医药（600196）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622000486?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:02","pubTimestamp":1774476154,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期复星医药发布2025年年报。截至本报告期末，公司营业总收入416.62亿元，同比上升1.45%，归母净利润33.71亿元，同比上升21.69%。按单季度数据看，第四季度营业总收入122.68亿元，同比上升20.81%，第四季度归母净利润8.47亿元，同比上升11.59%。本报告期复星医药盈利能力上升，毛利率同比增幅4.38%，净利率同比增幅19.21%。该数据高于大多数分析师的预期，此前分析师普遍预期2025年净利润为盈利33.58亿元左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600006043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622401171","title":"复星医药(02196)拟派发末期股息每股0.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622401171","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622401171?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:34","pubTimestamp":1774395268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司拟派发末期股息每股0.39元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK4588","BK0060","BK0187","600196","02196","BK0175","BK0196","BK0028","BK1191","BK1515","BK0012","BK0183","BK4585","BK0096","BK1593","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067566","title":"复星医药(02196)控股子公司拟新增开展融资租赁业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621067566?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:53","pubTimestamp":1774356801,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，为进一步拓宽融资渠道，公司部分控股子公司拟与具备相应资质的融资租赁公司/金融租赁公司新增开展融资租赁业务，融资总额不超过人民币6.5亿元，包括：(1)以部分自有资产设备作为转让标的及租赁物开展售后回租、(2)以新购资产设备直租。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","600196","BK0096","BK0188","BK1191","BK1593","BK0060","BK0012","02196","BK0028","BK0175","BK0187","BK0196","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621757062","title":"复星医药：关于2026年续聘会计师事务所的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757062","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621757062?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:25","pubTimestamp":1774355100,"startTime":"0","endTime":"0","summary":"证券日报网讯3月24日，复星医药发布公告称，2026年3月24日，公司第十届董事会第二十五次会议审议通过了关于本公司2026年续聘会计师事务所及2025年会计师事务所报酬的议案，拟续聘安永华明会计师事务所（特殊普通合伙）为本公司2026年度境内财务报告和内部控制审计机构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682800769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1191","BK0012","BK0060","BK1515","BK0183","BK0028","BK0175","BK0187","BK1593","02196","600196","BK0196","BK0096","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069488","title":"复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069488","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621069488?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:16","pubTimestamp":1774350963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药(600196.SH，02196)公布2025年度经营业绩。复星医药以创新研发突破与全球化体系升级为双引擎，实现营业收入人民币416.62亿元，同比增长1.45%，其中，创新药品收入98.93亿元，同比增长29.59%;境外收入129.77亿元，同比增长14.87%，两大核心指标实现双增长，深化复星医药高质量发展的底层逻辑。归母净利润33.71亿元，同比增长21.69%;归母扣非净利润23.40亿元，同比增长1.12%;经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，高质量发展底座进一步夯实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1515","BK1593","BK1161","BK0188","BK0239","BK1574","BK0183","BK0175","BK0028","BK1191","BK0012","BK0187","600196","BK0096","02196","06978","BK0060","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621066835","title":"复星医药最新公告：2025年净利润33.71亿元同比增长21.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066835","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621066835?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:40","pubTimestamp":1774348850,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布年报，公司2025年实现营业收入416.62亿元，同比增长1.45%；归属于上市公司股东的净利润为33.71亿元，同比增长21.69%。拟10股派发现金红利3.90元(税前)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400033313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273402","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月20日股价下跌1.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620273402?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:15","pubTimestamp":1774016125,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，复星医药报收于24.86元，较前一交易日下跌1.58%，最新总市值为663.87亿元。该股当日开盘25.29元，最高25.54元，最低24.84元，成交额达3.13亿元，换手率为0.59%。近日，上海复星医药（集团）股份有限公司控股子公司复宏汉霖收到国家药品监督管理局批准，同意其自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗开展Ⅰ期临床试验。2025年12月，该药已获美国FDA批准开展Ⅰ期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","BK0096","BK0239","BK1191","BK0060","02196","BK0188","600196","BK0028","BK0012","BK0175","BK0183","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142119323","title":"复星医药子公司硫代硫酸钠注射液药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1142119323","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142119323?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:44","pubTimestamp":1774003475,"startTime":"0","endTime":"0","summary":"复星医药（600196）宣布，其子公司提交的硫代硫酸钠注射液药品注册申请已获得国家药品监督管理局（NMPA）正式批准。\n此次获批标志着该药物在中国市场的准入取得关键进展，有望为相关疾病治疗提供新的用药选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0187","BK0188","BK0175","BK0028","BK0012","BK0196","BK0060","BK0183","BK0239","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620789751","title":"复星医药(600196.SH)： HLX18用于多种实体瘤治疗开展Ⅰ期临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789751","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620789751?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:00","pubTimestamp":1773997246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告， 公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司（合称“复宏汉霖”）收到国家药品监督管理局关于同意 HLX18（即重组抗 PD-1 人源化单克隆抗体注射液）用于多种实体瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后于中国境内 1开展该药品的相关临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1515","BK0012","BK0060","BK0196","BK0187","BK0188","BK1191","BK1593","BK0175","600196","BK0183","BK0028","02196","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620789489","title":"复星医药(600196.SH)：硫代硫酸钠注射液药品注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789489","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620789489?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:57","pubTimestamp":1773997060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司重庆凯林制药有限公司就硫代硫酸钠注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于氰化物中毒，也可用于砷、汞、铅、铋、碘等中毒。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600196","BK0096","BK0187","BK1593","02196","BK0060","BK0183","BK0175","BK0239","BK1191","BK0012","BK0196","BK1515","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619464348","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月16日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619464348?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:40","pubTimestamp":1773672030,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，复星医药报收于25.61元，较前一交易日上涨0.23%，最新总市值为683.9亿元。近日，上海复星医药（集团）股份有限公司控股子公司复宏汉霖收到国家药监局批准，同意HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌治疗开展临床试验。复宏汉霖拟于条件具备后在中国境内开展相关临床研究。截至2026年3月16日，全球范围内尚无同类联合用药治疗方案获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600037042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1515","BK0183","600196","BK0187","BK0239","BK0096","BK0028","BK1191","BK0060","BK0188","BK1593","02196","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619645427","title":"复星医药(600196.SH)：HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌(sqNSCLC)治疗获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645427","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619645427?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:44","pubTimestamp":1773657849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌治疗开展临床试验的批准。复宏汉霖拟于条件具备后在中国境内开展该治疗方案的相关临床研究。截至本公告日期，于全球范围尚无同类联合用药治疗方案获批上市。截至2025年2月，集团现阶段针对该治疗方案的累计研发投入约为人民币0.93亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1191","BK0187","BK0012","BK0183","BK0188","BK1515","BK1593","BK0239","BK0060","02196","600196","BK0175","BK0196","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619045967","title":"复星医药最新公告：控股子公司用于治疗雄激素脱发的药品LBP-ShC4获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619045967","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619045967?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:50","pubTimestamp":1773654632,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海菌济健康科技有限公司收到国家药品监督管理局关于同意LBP-ShC4开展临床试验的批准。LBP-ShC4是复星医药自主研发的活体生物治疗产品，拟用于治疗雄激素脱发（AGA）。截至2026年2月，针对LBP-ShC4的累计研发投入约为0.20亿元。截至本公告日期，于全球范围尚无用于治疗雄激素脱发（AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600025145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","BK0012","BK0060","BK1515","BK0183","BK0028","BK0175","BK0187","BK1593","02196","600196","BK0196","BK0096","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619127710","title":"每周股票复盘：复星医药（600196）三款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127710","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619127710?lang=zh_cn&edition=full","pubTime":"2026-03-15 01:40","pubTimestamp":1773510018,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，复星医药报收于25.55元，较上周的25.91元下跌1.39%。本周，复星医药3月10日盘中最高价报26.23元。本周关注点公司公告汇总：复星医药三款自研新药获临床试验批准。复星医药控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局批准，同意其自主研发的口服小分子创新药FXS0683片用于血液系统恶性肿瘤开展临床试验。复星医药产业拟于条件具备后在中国境内开展I期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","02196","BK0060","BK0012","600196","BK0028","BK0096","BK1515","BK0188","BK0183","BK0187","BK0239","BK1191","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619719840","title":"复星医药(600196.SH)控股子公司FXS0683片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719840","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619719840?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:30","pubTimestamp":1773394256,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司(简称“复星医药产业”)收到国家药品监督管理局关于同意FXS0683片(简称“FXS0683”)用于血液系统恶性肿瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0683的I期临床研究。","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0012","BK0060","600196","BK0188","02196","BK1191","BK0028","BK0183","BK1593","BK0196","BK1515","BK0239","BK0096","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775097197613,"stockEarnings":[{"period":"1week","weight":0.0674},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0219},{"period":"6month","weight":-0.0928},{"period":"1year","weight":0.0634},{"period":"ytd","weight":0.0219}],"compareEarnings":[{"period":"1week","weight":0.0043},{"period":"1month","weight":-0.056},{"period":"3month","weight":-0.0051},{"period":"6month","weight":0.0169},{"period":"1year","weight":0.1792},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}